1Spasova I, Petera J, Hytych V. The role of neoadjuvant chemotherapy in marginally resectable or unresectable stage III non-small cell lung cancer[J]. Neoplasma. 2002,49(3):189-196. 被引量：1
2Machtay M,Lee J H,Stevenson J P,et al.Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response[J]. J Thorac Cardiovasc Surg. 2004,127(1):108-113. 被引量：1
3Ferguson M K.Optimal management when unsuspected N2 nodal disease is identified during thoracotomy for lung cancer: costef fectiveness analysis [J]. Thorac Cardiovasc Surg2003 ,126 (6):1935-1942. 被引量：1
4Nagai K,Tsuchiya R,Mori T,et al. Randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage ⅢA N2 non-small cell lung cancer (JCOG9209) [J]. Thorac Cardiovasc Surg, 2003,125(2):254-260. 被引量：1
5Ramnath N, Sommers E,Robinson L, et al. Phase II study of neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small cell lung cance[J]. Chest, 2005,128(5):3467-3474. 被引量：1
6Muraoka M,Oka T,Akamine S,et al. Postoperative complications of pulmonary resection after platinum-based induction chemotherapy for primary lung cancer[J].Surg Today, 2003,33(1):1-6. 被引量：1
7Grossi F, Pennucci M C, Serrano J,et al.Phase II study of neoadjuvant chemotherapy in patients with surgically-proven, unresectable stage III non-small cell lung cancer[J].Anticancer Res, 2002,22(6B):3519-3524. 被引量：1
9Cerfolio RJ,Bryant AS,Winokur TS,et al. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer[J]. Ann Thorac Surg,2004,78(6): 1903-1909. 被引量：1
二级参考文献10
1[1]Goss G, Paszat L, Newman TE, et al. Use of preoperative chemotherapy with or without postoperative radiotherapy in technically respectable stage Ⅲ non-small cell lung cancer [J]. Cancer Prev Control, 1998, 2(1):32～39 被引量：1
2[2]Boer RH, Smith IE, Pastorino U, et al. Preoperative chemotherapy in early stage resectable non-small cell lung cancer: a randomized feasibility study justifying a multicenter phase Ⅲ trial [J]. Br J Cancer, 1999, 79(9):1514～1518 被引量：1
3[4]Ukena D. Chemotherapy in stage Ⅰ + Ⅱ non-small cell lung cancer[J]. Lung Cancer, 2001, 33(1):25～28 被引量：1
4[5]Murren JR, Buzaid AC, Hait WN, et al. Critical analysis of neoadjuvant therapy for stage Ⅲ a non-small cell lung cancer[J].Am Rev Resp Dis, 1991, 143(4): 889～894 被引量：1
5[6]Tsuchiya Y, Onda M, Sasajima K, et al. Effect of preoperative chemotherapy on metastatic lymph nodes in esophageal squamous cell carcinoma[J]. Dis Esophagus, 2002, 15(3): 226～231 被引量：1
6[7]Noda H, Kakeji Y, Kusumoto T, et al. Effectiveness of preoperative chemotherapy for far advanced gastric cancer [J]. Hepatogastroenterology, 2002, 49(44):379～382 被引量：1
7[8]Einhorn LH. Neoadjuvant and adjuvant trials in non-small cell lung cancer[J]. Ann Thorac Surg, 1998, 65(1):208～211 被引量：1
8[9]Iacobelli S, Irtelli L, Sacco R, et al. A phase study of neoadjuvant therapy with cisplatin and VP-16 for stage Ⅲ non-small cell lung cancer[J]. Anticancer Res, 1998, 18(3):2081～ 2084 被引量：1
9[10]Spasova I, Petera J, Hytych V. The role of neoadjuvant chemotherapy in marginally resectable or unresectable stage Ⅲnon-small cell lung cancer[J]. Neoplasma, 2002, 49(3):189 ～ 196 被引量：1
